FinlandFinland

Genes play a role in lighting up

12.05.2010

Reykjavik – Researchers from the Icelandic bio­tech company deCODE – together with colleagues from 23 institutions in a dozen countries – have determined that genetic factors influence both nico­tine dependence and the incidence of lung cancer. Cigarette smoking is a major cause of illness and death worldwide. The behaviour is a complex one, with variables ranging from how much people smoke to how hard they find it to quit. The impact of long-term smoking on health also varies greatly among individuals. A substantial portion of this variability is genetic, the researchers have now revealed. “Smoking is bad for any­one’s health. But it is even worse for some, and our discoveries continue to strengthen our ability to identify who those people are and give them a compelling additional reason to quit,” said Kári Stefánsson, Executive Chairman at deCODE. Two years ago, deCODE discovered the first common, single-letter variation (SNP) in the sequence of the human genome, on chromosome 15q25, to be associated with nicotine addiction and the risk of lung cancer. Now the scientists have stated that common SNPs on chromo­somes 8p11 and 19q13 among smokers increase the number of cigarettes smoked per day (CPD) – a measure of nicotine addiction – and indicate an increased risk of lung cancer. Published on April 25th in the online edition of Nature Genetics, the study analyses detailed genotypic and smoking data from more than 130,000 participants.

FinlandFinland

08.03.2012

The vaccine research centre of the University of Tampere in Finland has out­licenced a candidate combined prophylactic vaccine against norovirus and rota­virus infections. The Japanese vaccine venture UMN Pharma Inc. acquired the...

FinlandFinland

07.03.2012

Finnish protein manufacturer Vectron Biosolutions AS has completed a study comparing different expression technologies. According to Vectron, their proprietary E. coli expression technology gave higher yields for seven out of ten...

FinlandFinland

02.03.2012

Lappeenranta – Finnish paper industry major UPM plans to invest in an industry-scale biorefinery producing biofuels from crude tall oil, a by-product of the wood pulp manufacturing process. UPM’s total investment will amount to...

FinlandFinland

18.12.2011

Helsinki/Göttingen – Finnish laboratory supplier Biohit Oyj has sold its liquid handling business for €68m to German process and labtech provider Sartorius AG. Osmo Suovaniemi, founder and Chairman of the Board at Biohit,...

FinlandFinland

17.12.2011

Porvoo/Chalfont St. Giles – GE Healthcare and Neste Jacobs have formed a strategic alliance to drive worldwide self-sufficiency in blood plasma fractionation. Finnish-based Neste Jacobs Oy, a global expert in plant engineering...

FinlandFinland

31.10.2011

Bresso/Turku – The wedding's off between Newron and Biotie. The bride has run away. Shares in Italy's Newron Pharmaceuticals plunged after its proposed merger with Biotie Therapies Corp was called off by the Finnish firm....

FinlandFinland

28.09.2011

Turku/ Bresso – It is both good and bad news for the Italian biotechnology sector: Finnish Biotie Therapies ASA has signed an agreement to acquire Newron Pharmaceuticals S.p.A. for €45 million. On the down side, Italy loses one...

FinlandFinland

04.04.2011

Hafnarfjodur – Actavis Group CEO Claudio Albrecht announced at the beginning of February that the company may go public within the next 2-3 years, although it isn’t clear whether the generics manufacturer would conduct an IPO,...

Displaying results 1 to 10 out of 96

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-finland/article/genes-play-a-role-in-lighting-up.html

Print Magazine

Product of the week

Products

Events

All Events

Partner-Events

Stock list

All quotes

TOP

  • CYTOS0.28 CHF21.74%
  • CO.DON2.57 EUR7.08%
  • EPIGENOMICS5.12 EUR5.57%

FLOP

  • BIOTEST80.10 EUR-2.17%
  • WILEX2.15 EUR-1.83%
  • BIOFRONTERA2.46 EUR-1.60%

TOP

  • CYTOS0.28 CHF86.7%
  • EPIGENOMICS5.12 EUR49.7%
  • STRATEC BIOMEDICAL49.10 EUR30.9%

FLOP

  • BIOFRONTERA2.46 EUR-15.5%
  • ADDEX3.10 CHF-9.9%
  • CO.DON2.57 EUR-8.9%

TOP

  • SANTHERA90.75 CHF2569.1%
  • CO.DON2.57 EUR144.8%
  • BB BIOTECH180.60 EUR62.8%

FLOP

  • CYTOS0.28 CHF-91.8%
  • 4SC0.92 EUR-47.1%
  • THERAMETRICS0.07 CHF-46.2%

No liability assumed, Date: 20.11.2014

Current issue

All issues